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B R I E F  R E P O R T
Ferritin to Erythrocyte Sedimentation Rate Ratio: Simple 
Measure to Identify Macrophage Activation Syndrome in 
Systemic Juvenile Idiopathic Arthritis
Esraa M. A. Eloseily,1 Francesca Minoia,2 Courtney B. Crayne,3  Timothy Beukelman,3 Angelo Ravelli,4  and 
Randy Q. Cron3
Objective. Macrophage activation syndrome (MAS) is a life‐threatening complication of systemic juvenile idio-
pathic arthritis (sJIA). Early diagnosis is critical. Classification criteria for MAS in sJIA perform less well in the setting 
of cytokine‐directed therapies. The goal herein was to explore a simple ratio of serum ferritin to the erythrocyte sed-
imentation rate (ESR) for diagnosis of MAS in the setting of sJIA, and to assess ferritin alone as a screening tool for 
identifying MAS of multiple etiologies.
Methods. Data from a large international cohort of sJIA patients with and without MAS, and from hospitalized 
patients with systemic infection (SI), were assessed for the ferritin:ESR ratio and ferritin alone to identify MAS among 
sJIA patients. Moreover, data from a smaller cohort of MAS patients associated with multiple etiologies and febrile 
hospitalized controls were explored. For both cohorts and controls, receiver operating characteristic curves (ROCs) 
for the ferritin:ESR ratio and ferritin alone were constructed, and areas under the curves (AUCs) were calculated. The 
Youden index was used to determine the optimal ferritin:ESR ratio and ferritin alone cut points for diagnosis.
Results. A ferritin:ESR ratio of 21.5 was 82% sensitive and 78% specific for diagnosing sJIA‐MAS versus active 
sJIA without MAS. Ferritin alone with a set sensitivity of 95% (screening tool) had an 89.3% specificity of identifying 
all‐cause MAS versus febrile hospitalized children.
Conclusion. The ferritin:ESR ratio is a practical tool for diagnosing MAS among sJIA patients, and serum ferritin 
alone is a remarkable screening tool for identifying MAS among febrile hospitalized children.
INTRODUCTION
Macrophage activation syndrome (MAS) is a form of second-
ary hemophagocytic lymphohistiocytosis (sHLH) that complicates 
rheumatologic disorders. MAS is a potentially life‐threatening con-
dition, most commonly identified in children with systemic juvenile 
idiopathic arthritis (sJIA) and, to a lesser degree, in the adult equiv-
alent, adult‐onset Still disease (AOSD) (1). MAS is characterized 
by a dysregulation of the immune response, with a continuous 
activation and expansion of T lymphocytes and macrophages 
leading to a cytokine storm and ultimately resulting in multiorgan 
system failure (2).
Although MAS has been known to complicate other rheu-
matic disorders, specifically systemic lupus erythematosus (SLE) 
and Kawasaki disease (KD), much of the knowledge regarding the 
pathophysiology, clinical presentation, and treatment is derived 
from sJIA cohorts. The prevalence of MAS within the sJIA popu-
lation is estimated to be 10%; however, reports suggest that the 
number of sJIA patients with subclinical MAS may be as high as 
40% (3). sJIA and MAS share many clinical and laboratory fea-
tures, and early recognition of MAS is crucial because timely treat-
ment is important for survival.
Diagnostically, MAS is similar to sHLH in that presenting 
features include high unremitting fever, hyperferritinemia, pan-
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cytopenia, hepatosplenomegaly, and hypofibrinogenemia. Both 
conditions can be associated with other laboratory abnormalities, 
including elevated D‐dimers, liver enzymes, and triglycerides. Sol-
uble interleukin (IL)‐2 receptor α‐chain (sCD25) may be elevated, 
but testing is often not available at an on‐site laboratory and there-
fore is not routinely done at the time of diagnosis. Bone marrow 
biopsy is often inconclusive. Although histopathology reveal char-
acteristic increased hemophagocytic activity with positive CD163 
(histiocyte) staining, this feature is often not present in initial stages 
nor is it highly sensitive or specific for MAS (4).
A major diagnostic obstacle is the absence of a single 
pathognomonic feature. Furthermore, the overlapping clinical and 
laboratory features MAS shares with other inflammatory diseases 
make universal diagnostic criteria near impossible. Using real 
patient data and comparable controls from a cohort of 1100 sub-
jects in 33 countries, classification criteria for MAS in patients with 
sJIA were developed and published in 2016. The criteria proved 
to be both sensitive (0.73) and specific (0.99). In any febrile patient 
with confirmed or suspected sJIA, a diagnosis of MAS requires a 
serum ferritin level greater than 684 ng/ml plus any two of the fol-
lowing: platelet count 181 × 109/L or less, aspartate aminotrans-
ferase of more than 48 units/L, trigylceride greater than 156 mg/
dl, or fibrinogen 360 mg/dl or lower (5). Unlike sCD25, these few 
labs are relatively inexpensive and usually readily available. The 
criteria have been validated in sJIA and applied to AOSD patients 
(5,6), but they may not prove to be the most accurate diagnostic 
tool for MAS in other systemic inflammatory conditions like SLE or 
KD. Moreover, in the setting of biologic therapies for sJIA (eg, tar-
geting IL‐1 or IL‐6), these criteria perform less well (7). Other more 
complicated criteria have been proposed for identifying sHLH (pri-
marily in the setting of cancer) (8), but a quick and easy way of 
diagnosing sHLH/MAS is needed.
A significant rise in serum ferritin (eg, greater than 10 000 
ng/ml) in the setting of a hospitalized febrile patient is a simple 
screening tool for sHLH/MAS. Although the ferritin levels usually 
rise in cases of sHLH/MAS, the ESR, although initially elevated as 
a nonspecific sign of inflammation, may be surprisingly low. The 
fall in ESR occurs secondary to fibrinogen (a major driver of the 
ESR) degradation as part of the consumptive coagulopathy, and 
decreased synthesis that is due to liver dysfunction, that occur 
in sHLH/MAS (2). Based on this, the ratio of ferritin to ESR is 
expected to rise in MAS. Gorelik et al reported that a ferritin:ESR 
ratio [ferritin (ng/ml) divided by ESR (mm/hr)] of greater than 80 
showed a sensitivity and specificity of 100% in distinguishing 
MAS from new‐onset sJIA without MAS in a small (n = 28) cohort 
(9). Thus, the ferritin:ESR ratio shows promise as an inexpensive 
and quick calculation to rapidly diagnose MAS, prevent delay in 
treatment, and improve outcomes. Therefore, we evaluated the 
ferritin:ESR ratio, and ferritin alone, as diagnostic and/or screen-
ing tests for the presence of sHLH/MAS in a large multinational 
cohort of sJIA patients (n = 524) and in a cohort of pediatric sHLH 
patients (n = 52) with multiple underlying etiologies.
PATIENTS AND METHODS
Data were reviewed from a multinational study of patients 
with sJIA‐MAS (n = 362), sJIA flare without MAS (n = 404), and 
hospitalized systemic infections (SIs) (n = 345) (same data used 
to develop the American College of Radiology (ACR)–European 
League Against Rheumatism (EULAR) sJIA‐MAS criteria for sJIA‐
MAS) (5). Patients without documented ESR and ferritin were 
excluded, leaving 262 sJIA‐MAS, 262 sJIA flare, and 93 patients 
with SI.
In addition, a second patient population was evaluated 
to explore the ability of the ferritin:ESR ratio not only to dis-
tinguish patients with sJIA‐MAS from patients with sJIA flare 
without MAS but to also distinguish sHLH/MAS with any 
potential underlying etiology from febrile hospitalized patients 
without sHLH/MAS. The electronic medical records (EMRs) 
at Children’s of Alabama (CoA) were searched for all patients 
diagnosed with sHLH/MAS (ICD9‐288.4, ICD10‐D76.1) from 
January 2008 through December 2016 regardless of under-
lying etiology. All primary HLH patients were excluded. All 
included patients satisfied at least one of five published sets 
of criteria: HLH‐2004 (10), HLH‐2009 (11), SLE MAS (12), 
sJIA MAS‐2016 (5), and HScore (8). The EMR was searched 
for age and sex‐matched comparator patients hospitalized 
over the same time frame with fever and had both ferritin and 
ESR tested. For patients with multiple hospital admissions, 
data from their first visit was reported. For all patients, the 
first ferritin tested during the hospital admission was docu-
mented with the closest ESR measured within a timeframe of 
48 hours before or after the ferritin. Patients were excluded for 
the following reasons: sickle cell disease, hemochromatosis, 
receipt of multiple blood transfusions prior to the measure-
ment of ferritin, receipt of intravenous immunoglobulin prior to 
ESR measurement, age less than 1 year, and sJIA with MAS. 
There were 52 sHLH/MAS patients and 159 febrile compara-
tor patients identified (Supplemental Table 1).
Table 1. Sensitivity and specificity of the cut points for ferritin:ESR 
ratio and ferritin alone in cases of sJIA‐MAS vs active sJIA and sJIA‐
MAS vs SI
 
sJIA‐MAS vs Active 




Sensitivity 82% Sensitivity 91%
Specificity 78% Specificity 93%
Ferritin cut point 
(ng/ml)
1,045 396.6
Sensitivity 84% Sensitivity 92%
Specificity 66% Specificity 95%
Abbreviation: ESR, erythrocyte sedimentation rate; MAS, macro-
phage activation syndrome; SI, systemic infections; sJIA, systemic 
juvenile idiopathic arthritis.
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Using the ACR‐EULAR multinational data, patients with 
sJIA‐MAS were compared with patients with sJIA without MAS 
and with patients with SI; additionally, using the CoA EMR 
data, patients with sHLH/MAS were compared with patients 
with febrile illness. Receiver operating characteristic curves 
(ROCs) for the ferritin:ESR ratio and ferritin alone were con-
structed, and areas under the curves (AUCs) were calculated 
with 95% confidence intervals. The Youden index was used to 
determine the optimal ferritin:ESR ratio and ferritin alone cut 
points for diagnosis. Cut points that produced 95% sensitivity 
were identified, and the corresponding specificity was deter-
mined to evaluate the utility of the ferritin:ESR ratio and ferritin 
alone as screening tests for sHLH/MAS.
RESULTS
Comparing sJIA‐MAS with sJIA flare without MAS, the mul-
tinational data showed the ferritin:ESR ratio, with an optimal cut 
point value according to the Youden index of 21.5, had sensitivity 
of 82% and specificity of 78% [AUC: 0.87 (0.84‐0.90)] (Supple-
mental Figure 1A, Table 1). Ferritin alone, with a cut point of 1045 
mg/dl, had sensitivity of 84% and specificity of 66% (AUC: 0.81 
[0.78‐0.84]) (Supplemental Figure 1B, Table  1). These results 
were comparable to the ACR‐EULAR sJIA‐MAS criteria, which 
had an AUC of 0.86 with a lower sensitivity (73%) but a higher 
specificity of 99% (Table 2).
When assessing performance at a 99% specificity for use 
as a diagnostic test, the ferritin:ESR ratio yielded 46% sensitivity, 
whereas the ACR‐EULAR sJIA‐MAS criteria set a 99% sensitivity 
and resulted in 73% sensitivity (Table 2). When assessing perfor-
mance at the 95% sensitivity level for use as a screening test for 
sJIA‐MAS, the ferritin:ESR ratio at a cut point of 4.9 or greater 
had specificity of 41%, whereas the ferritin at a cut point of 225 
ng/ml or more had specificity of 31% (Table  3). Therefore, for 
MAS‐sJIA versus active sJIA, ferritin alone does not discriminate 
as well as the ferritin:ESR ratio.
Comparing sJIA‐MAS cases versus infections using the 
data from the multinational study, a ferritin:ESR ratio at a cut 
point of 11.3 had a sensitivity of 91% and specificity of 93% 
[AUC: 0.95 (0.92‐0.97)] (Supplemental Figure 2A, Table 1)). Fer-
ritin alone, with a cut point of 396.6 ng/ml, was found to have 
sensitivity of 92% and specificity of 95% [AUC: 0.97 (0.95‐0.98)] 
(Supplemental Figure 2B, Table 1). When assessing performance 
at 95% sensitivity in order to evaluate their utility as screening 
tests, the ferritin:ESR ratio at a cut point of 4.9 or greater had 
specificity of 78%, whereas the ferritin alone at a cut point of 225 
mg/dl or more had specificity of 85% (Table 3). Therefore, ferri-
tin alone discriminated better than the ferritin:ESR ratio between 
patients with sJIA‐MAS and febrile patients with infection.
Comparing patients with sHLH/MAS with variable underly-
ing etiologies versus febrile hospitalized patients (Supplemental 
Table 1), the ferritin:ESR ratio, with the previously defined cut 
point of 11.3 (for MAS vs SI), yielded sensitivity of 92% and 
specificity of 86% [AUC 0.96 (0.93‐0.99)] (Supplemental Figure 
3A). When using the optimal cut point obtained by the Youden 
index from these current data, which was 14.4, the sensitivity 
remained the same at 92% and specificity improved to 89%. 
Using ferritin alone, a cut point of 969 ng/ml has a sensitivity of 
90% and a specificity of 96% [AUC is 0.98 (0.95‐0.99)] (Supple-
mental Figure 3B). When assessing performance at 95% sensi-
tivity, the ferritin:ESR ratio at a cut point of 4.32 or greater had 
Table 2. Comparison between the ferritin:ESR ratio and the ACR‐







Sensitivity at 99% 
specificity
46% 73%
Abbreviation: ACR, American College of Rheumatology; AUC, area 
under the curve; ESR, erythrocyte sedimentation rate; EULAR, Eu-
ropean League Against Rheumatism; MAS, macrophage activation 
syndrome; sJIA, systemic juvenile idiopathic arthritis.
Table 3. Specificity of ferritin:ESR ratio and ferritin alone at 95% sensitivity in cases of sJIA‐MAS vs sJIA, sJIA‐MAS vs 
SI, and all cause MAS vs febrile patients (CoA data)
Comparison Laboratory Test
Specificity at 95% 
Sensitivity Cut Point
sJIA‐MAS vs sJIA flare (ACR‐EULAR data) Ferritin:ESR 41.1% ≥4.9
Ferritin alone 30.7% ≥225
sJIA‐MAS vs SI (ACR‐EULAR data) Ferritin:ESR 77.9% ≥4.9
Ferritin alone 85.2% ≥225
All cause MAS vs Fever (CoA data) Ferritin:ESR 65.4% ≥4.32
Ferritin alone 89.3% ≥627
Abbreviation: ACR, American College of Rheumatology; CoA, Children’s of Alabama; ESR, erythrocyte sedimentation 
rate; EULAR, European League Against Rheumatism; MAS, macrophage activation syndrome; SI, systemic infections; 
sJIA, systemic juvenile idiopathic arthritis.
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a specificity of 65%, whereas the ferritin alone at a cut point of 
627 ng/ml or more had specificity of 89% (Table 3). Thus, the 
ferritin alone was a good screening test for identifying all causes 
of sHLH/MAS when compared with febrile hospitalized patients 
as comparators.
DISCUSSION
Several criteria have been proposed to diagnose HLH/MAS. 
One of the most commonly employed guidelines is the HLH‐2004 
criteria (10). The HLH‐2004 guidelines were initially intended to 
diagnose familial HLH; thus, they are often too restrictive for early 
diagnosis of sHLH/MAS. In addition, they are not timely when 
early diagnosis and treatment are critical for survival. It might take 
several days to get all the labs reported, especially sCD25 and 
natural killer cell function, typically sent to a remote lab. Moreover, 
bone marrow biopsy might be delayed or not done because of the 
patient’s clinical condition. The HLH‐2004 guidelines were previ-
ously shown to perform poorly in identifying MAS among a large 
cohort of sJIA patients (1). The HScore is another tool used to 
identify sHLH/MAS, but it is cumbersome to perform and requires 
several labs, including bone marrow aspiration, to identify hemo-
phagocytosis (8). Moreover, it was originally developed from data 
of patients with primarily malignancy‐related HLH. There has also 
been a trend to establish diagnostic guidelines for MAS compli-
cating different underlying rheumatic disorders like systemic SLE 
(13) and sJIA (14). Although these are more specific and tailored 
to the underlying disease, they might not be as helpful for newly 
diagnosed cases presenting with MAS where the disorder is not 
yet diagnosed. Therefore, one set of criteria for all causes of sHLH/
MAS that is timely and feasible will be valuable.
The current study objective was to find simplistic and timely 
criteria using labs that would be readily available in most hospitals 
within 24 hours. In addition to establishing a sHLH/MAS diagno-
sis, we explored identifying a screening test to raise an alarm for 
the possibility of MAS. Results from a simple screen will allow cli-
nicians to proceed to further investigations to confirm the sHLH/
MAS diagnosis or to help exclude a diagnosis of sHLH/MAS for 
the meantime.
Two relevant, inexpensive, and timely labs are the serum 
ferritin and ESR. Typically, the ferritin level rises in cases of sHLH/
MAS, whereas the ESR drops. A falling ESR suggests fibrino-
gen consumption and decreased production, and it has been 
established as an early lab finding in sJIA complicated by MAS 
(15). Although fibrinogen is an acute phase reactant, it gets con-
sumed as the coagulopathic state of MAS ensues. In compari-
son, the serum ferritin level is not expected to be markedly raised 
in sJIA flare (not greater than 684 ng/ml per the ACR‐EULAR 
criteria) (5), but the ESR is usually notably increased, driven by 
inflammation. Therefore, the higher the ratio of ferritin to ESR, 
the higher the likelihood the case is complicated by MAS (14). In 
2013, Gorelik et al reported a case‐control study of 28 patients 
with sJIA, 7 of whom developed MAS, and matched them with 
age‐, race‐, and gender‐similar controls (n = 30). A ferritin:ESR 
greater than 80 showed a sensitivity and specificity of 100% in 
distinguishing MAS from new‐onset sJIA. When the ratio was 
lowered to more than 37, the sensitivity remained 100% while 
the specificity decreased to about 90% (9). This appeared prom-
ising for distinguishing MAS from sJIA flare in this small cohort.
Herein, using a large sJIA cohort, the AUC was calculated to 
find the optimal cut point of ferritin:ESR ratio and ferritin alone that 
differentiates between sJIA‐MAS versus active sJIA, sJIA‐MAS 
versus patients with SI, and MAS versus both. The ferritin to ESR 
ratio was better than ferritin alone in differentiating the sJIA‐MAS 
group from the active sJIA flare with a cut point of 21.5. In the 
study by Gorelik et al, the ferritin:ESR ratio was superior to ferritin 
alone, sCD25, and follistatin‐like protein 1 in discriminating MAS 
from new‐onset sJIA. In their study, a ferritin:ESR ratio greater 
than 80 provided statistically optimal sensitivity and specificity (9). 
The discrepancy in the cut points between our study and theirs 
could be attributed to the small numbers (n = 28 with sJIA, 7 with 
MAS) in their study. In our study, ferritin alone was slightly bet-
ter than the ferritin:ESR ratio in differentiating sJIA‐MAS patients 
from patients with SI with a cut point of 396.6 ng/ml. However, 
between the two approaches, the sensitivities and specificities 
were comparable.
Our results have further shown that to differentiate sJIA‐MAS 
from sJIA flare, ferritin alone does not discriminate as well as the 
ferritin:ESR ratio. Conversely, ferritin alone discriminated slightly 
better than the ferritin:ESR ratio between patients with sJIA‐MAS 
and febrile SI patients. Thus, serum ferritin alone can be used as 
an initial screening tool for MAS in febrile hospitalized patients to 
consider obtaining other MAS markers (eg, transaminases, lactic 
acid dehydrogenase, triglycerides, D‐dimers, etc).
In addition to helping to differentiate sJIA‐MAS from sJIA 
flare without MAS, we explored the utility of the ferritin:ESR 
ratio in discriminating sHLH/MAS of multiple etiologies from 
febrile hospitalized controls without MAS in a separate cohort. 
Interestingly, the ferritin:ESR ratio performed quite well in distin-
guishing MAS associated with multiple conditions from hospi-
talized febrile children without MAS. However, the ferritin alone 
performed even better. This furthers an argument to be made 
for obtaining an initial screening serum ferritin for all hospitalized 
febrile patients (2).
In summary, the serum ferritin:ESR ratio (with a cut point 
of 21.5 or greater) is a simple, timely, sensitive, and reasonably 
specific tool that distinguishes sJIA‐MAS from active sJIA with-
out MAS. This ratio performs comparably to the ACR‐EULAR 
criteria for the diagnosis of MAS but with lower specificity. Nev-
ertheless, serum ferritin alone is sufficient to screen for MAS from 
all causes among febrile hospitalized patients (cut point 627 ng/
ml or greater). We suggest that other centers validate the ferrit-
in:ESR ratio and ferritin alone as diagnostic and screening tools 
for MAS in different patient populations.
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